Alendronate Increases BMD in Men With Prostate Cancer Receiving Androgen Deprivation Therapy

March 22, 2007 — In men with nonmetastatic prostate cancer who received androgen deprivation therapy (ADT), 70 mg of alendronate once weekly prevented bone mass loss, according to the results of a randomized controlled trial reported in the March 19 issue of the Annals of Internal Medicine.
"Androgen deprivation therapy (ADT) in men with prostate cancer is associated with bone loss and fractures," write Susan L. Greenspan, MD, from the University of Pittsburgh in Pennsylvania, and colleagues. "Because prostate cancer is a common and growing problem and an increasing number of men are receiving ADT, we sought to determine whether once-weekly alendronate would improve bone mass and reduce bone turnover in men with nonmetastatic prostate cancer receiving ADT."
http://www.medscape.com/viewarticle/553989?rss